UBS lowered the firm’s price target on Regeneron (REGN) to $633 from $768 and keeps a Neutral rating on the shares. The Eyelea shadow continues to loom over the stock, and the transition to Eyelea HD will take longer, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $587 from $652 at Baird
- Regeneron price target lowered to $800 from $865 at BMO Capital
- Regeneron price target lowered to $700 from $750 at Wells Fargo
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
- Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments